CVR 25540417Private limited company (ApS)Engroshandel med medicinalvarer og sygeplejeartikler (464610)GentofteFounded 28 Jun 2000
CVR registers no owner holding 5% or more.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about ARROW PHARMA ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
CVR, 2013
Gross profit
999K
DKK, annual report 2013
Result
+343.8K
DKK, annual report 2013
Equity
-13.3M
DKK, annual report 2013
CVR registers no owner holding 5% or more.
Henriette Sideniusuntil 22 Dec 2014
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
2013, annual: 1 employee, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 0 | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 2 | No count | No count | No count | No count | 2 | 2 | 1 |
| FTE | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest 2013, published 14 May 2016.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2013, DKK: Operating profit 222.3K, Result for the year 343.8K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2013, DKK: Total assets 1.6M, Equity -13.3M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2009 | 2010 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|
| Gross profit | Not reported | Not reported | Not reported | Not reported | 999 |
| Operating profit | Not reported | Not reported | Not reported | -1,439 | +222 |
| Result for the year | Not reported | Not reported | Not reported | -1,805 | +344 |
| Equity | Not reported | Not reported | Not reported | -13,637 | -13,293 |
| Total assets | Not reported | Not reported | Not reported | 15,403 | 1,581 |
| Employees (average) | Not reported | Not reported | Not reported | 1 | 1 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | Not reported | Not reported | Not reported | 0% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for ARROW PHARMA ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 14,500,000, cash price 14,500,000.00, implied value 3,262,514,500,000 | 14,500,000.00 | 14,500,000 | 3,262,514,500,000 | 225,001 | |
| IncreaseDebt conversion, cashPaid in 12,000,000, cash price 120.00, implied value 27,000,000 | 120.00 | 12,000,000 | 27,000,000 | 225,000 | |
| FoundingNot read from the announcement | None | None | None | 125,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Merger (fusion), as the ceasing company (ophørende selskab)
Source: CVR, read 17 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 17 Nov 2026.
18 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en fusionsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende selskaber må antages at være tilstrækkeligt sikrede efter fusionen.
Selskabet opløst efter fusion med CVR-NR. 31423392 ARROW ApS.
Erhvervsstyrelsen har modtaget oplysning om,
at der påtænkes gennemført en fusion mellem
CVR-NR. 25540417 ARROW PHARMA ApS (ophørende).
CVR-NR. 31423392 ARROW ApS (fortsættende), og
kapitalejerne har i enighed besluttet, at der ikke skal
udarbejdes en fusionsplan.
Kapitalejerne i.
CVR-NR. 25540417 ARROW PHARMA ApS.
CVR-NR. 31423392 ARROW ApS, har i enighed
besluttet, at der ikke skal udarbejdes en erklæring om
kreditorernes stilling i forbindelse med fusionen.
Kreditorer, hvis fordringer er stiftet forud for
bekendtgørelsen om fusionen, og for hvilke der ikke er
stillet særskilt sikkerhed, kan anmelde deres fordringer
senest 4 uger efter at den endelige beslutning om fusion
er truffet.
Vedtægter ændret:
05.09.2014.
Kapitalforhøjelse:
kr. 1,00 indbetalt kontant, kurs 1.450.000.000,00.
Kapitalen udgør herefter kr. 225.001,00.
Vedtægter ændret:
21.03.2014.
Bestyrelse:
Udtrådt af bestyrelsen:
Jan Erik Anders Jungbeck, den 21.03.2014.
Indtrådt i bestyrelsen:
Ólöf Thorhallsdottir, den 21.03.2014.
Direktion:
Udtrådt af direktionen:
Jan Erik Anders Jungbeck, den 21.03.2014.
Indtrådt i direktionen:
Henriette Sidenius, den 21.03.2014.
Bestyrelse:
Udtrådt af bestyrelsen:
Björn Gudlaugur Adalsteinsson, den 16.10.2013.
Indtrådt i bestyrelsen:
Fabian Alexander Hopkins (formand), den 16.10.2013.
Revision:
Ny adresse:
c/o Actavis A/S, Ørnegårdsvej 16, 2820 Gentofte.
Ny kommune:
Gentofte.
Direktion:
Udtrådt af direktionen:
Torben Jung Laursen, den 11.03.2013.
Indtrådt i direktionen:
Jan Erik Anders Jungbeck, den 11.03.2013.
Bestyrelse:
Udtrådt af bestyrelsen:
Poul Mino Bisaro, den 11.03.2013, David Adam Buchen, den 11.03.2013, Torben Jung Laursen, den 11.03.2013.
Indtrådt i bestyrelsen:
Björn Gudlaugur Adalsteinsson (formand), den 11.03.2013, Anna Helena Bergström, den 11.03.2013, Jan Erik Anders Jungbeck, den 11.03.2013, David Vrhovec, den 11.03.2013.
Bestyrelse:
Udtrådt af bestyrelsen:
Jan Christer Tjernström, den 01.09.2011.
Indtrådt i bestyrelsen:
Direktør Torben Jung Laursen, den 01.09.2011.
Direktion:
Udtrådt af direktionen:
Jan Christer Tjernström, den 01.09.2011.
Indtrådt i direktionen:
Direktør Torben Jung Laursen, den 01.09.2011.
Ny adresse:
Sankt Peders Stræde 2, 1., 4000 Roskilde.
Ny kommune:
Roskilde.
Vedtægter ændret:
12.05.2010.
Bestyrelse:
Udtrådt af bestyrelsen:
Howard Stanely Simson, den 12.05.2010, Per Finn Lange, den 12.05.2010, Maria Celeste Meersohn, den 12.05.2010.
Indtrådt i bestyrelsen:
Poul Mino Bisaro (formand), den 12.05.2010, David Adam Buchen, den 12.05.2010, Jan Christer Tjernström, den 12.05.2010.
Direktion:
Udtrådt af direktionen:
Per Finn Lange, den 12.05.2010.
Indtrådt i direktionen:
Jan Christer Tjernström, den 12.05.2010.
Revision:
Udtrådt af revisionen:
KPMG C. Jespersen Statsautoriseret Revisionsinteressentskab, den 13.05.2008.
Indtrådt i revisionen:
KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, Stationsparken 31, 2600 Glostrup, den 13.05.2008.
Vedtægter ændret:
23.05.2005.
Kapitalforhøjelse kr. 100.000,00: kr. 91.204,00 indbetalt ved konvertering af gæld, kurs 12.000,00, kr. 8.796,00 indbetalt kontant, kurs 12.000,00.
Kapitalen udgør herefter kr. 225.000,00.
Bestyrelse:
Tiltrådt som formand:
Howard Stanely Simson, den 23.05.2005.
Indtrådt i bestyrelsen:
Direktør Carl Lennart Söderman (næstformand), den 23.05.2005.
Revision:
Udtrådt af revisionen:
FRITJOF DITTMANN STATSAUTORISERET REVISIONSAKTIESELSKAB, den 15.12.2004.
Indtrådt i revisionen:
KPMG C. Jespersen Statsautoriseret revisorinteressentskab, Borups Alle 177, Postboks 250, 2000 Frederiksberg, den 15.12.2004.
Vedtægter ændret:
05.02.2002.
Ny adresse:
Hovedgaden 41, 2., 2970 Hørsholm.
Ny kommune:
Hørsholm.
Vedtægter ændret:
23.08.2000.
Nyt navn:
ARROW PHARMA ApS.
Ny adresse:
c/o Per Lange, Henrikshave 56, 2950 Vedbæk.
Ny kommune:
Søllerød.
Bestyrelse:
Indtrådt i bestyrelsen:
Adm. direktør Per Finn Lange, den 18.08.2000, Marie Celeste Meersohn, den 18.08.2000, Howard Stanely Simson, den 23.08.2000.
Direktion:
Udtrådt af direktionen:
Jørgen Byriel, den 18.08.2000.
Indtrådt i direktionen:
Adm. direktør Per Finn Lange, den 18.08.2000.
Selskabet tegnes af 1 direktør eller 2 bestyrelsesmedlemmer i forening.
Revision:
Udtrådt af revisionen:
CVR-NR. 12523246 GROTHEN & PERREGAARD, STATSAUTORISERET REVISIONSAKTIESELSKAB, den 23.08.2000.
Indtrådt i revisionen:
CVR-NR. 72558014 FRITJOF DITTMANN STATSAUTORISERET REVISIONSAKTIESELSKAB, Greve Strandvej 18 B, 2670 Greve, den 23.08.2000.
Første regnskabsår:
28.06.2000 - 31.12.2001.
Stiftelsesdato:
28.06.2000.
Seneste vedtægtsdato:
28.06.2000.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 100,00.
Stifter:
CVR-NR. 10442486 KR 332 ApS, c/o Kromann Reumert, Rådhuspladsen 14, 1550 København V, den 28.06.2000.
Direktion:
Direktør Jørgen Byriel, den 28.06.2000.
Selskabet tegnes af en direktør.
Revision:
CVR-NR. 12523246 GROTHEN & PERREGAARD, STATSAUTORISERET REVISIONSAKTIESELSKAB, Stockholmsgade 45, 2100 København Ø, den 28.06.2000.
Første regnskabsår:
28.06.2000 - 31.12.2000.
Regnskabsår:
01.01 - 31.12.
P-number 1007823491Ørnegårdsvej 16, 2820 Gentofte